通过收集健康志愿者每小时的尿液来测定异喹胍代谢率。
Determination of debrisoquine metabolic ratio from hourly urine collections in healthy volunteers.
作者信息
Philip P A, James C A, Rogers H J
机构信息
Department of Clinical Pharmacology, United Medical School, Guy's Hospital, London.
出版信息
Br J Clin Pharmacol. 1987 Dec;24(6):827-9. doi: 10.1111/j.1365-2125.1987.tb03254.x.
Abstract
The possibility of simplifying the regimen for the collection of urine samples in the determination of the debrisoquine metabolic ratio (DMR) was explored in 15 normal subjects. In the extensive metaboliser subgroup (EM; n = 11), there was a close correlation between the DMR as determined by an 8 h urine collection and the debrisoquine/4-hydroxydebrisoquine ratio (D/4-OHD) in the hourly samples (excluding the first hour). In the poor metabolisers (PM; n = 4) the phenotype could be identified, but it was not possible to estimate the DMR reliably.
摘要
在15名正常受试者中探索了简化测定异喹胍代谢比率（DMR）时尿液样本采集方案的可能性。在广泛代谢者亚组（EM；n = 11）中，通过8小时尿液收集测定的DMR与每小时样本（不包括第一小时）中的异喹胍/4-羟基异喹胍比率（D/4-OHD）之间存在密切相关性。在代谢不良者（PM；n = 4）中，可以识别出其代谢表型，但无法可靠地估计DMR。
相似文献
1
Determination of debrisoquine metabolic ratio from hourly urine collections in healthy volunteers.通过收集健康志愿者每小时的尿液来测定异喹胍代谢率。
Br J Clin Pharmacol. 1987 Dec;24(6):827-9. doi: 10.1111/j.1365-2125.1987.tb03254.x.
2
3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.3,4-脱氢去甲丙咪嗪，一种由4-羟基去甲丙咪嗪形成的新型去甲丙咪嗪代谢物，它会影响CYP2D6代谢率。
Drug Metab Dispos. 2006 Sep;34(9):1563-74. doi: 10.1124/dmd.105.008920. Epub 2006 Jun 16.
3
Enantioselectivity of debrisoquine 4-hydroxylation in Brazilian Caucasian hypertensive patients phenotyped as extensive metabolizers.
J Chromatogr B Biomed Sci Appl. 2000 Dec 1;749(2):153-61. doi: 10.1016/s0378-4347(00)00402-3.
4
Debrisoquin oxidation polymorphism in a Spanish population.
Clin Pharmacol Ther. 1988 Jul;44(1):74-7. doi: 10.1038/clpt.1988.115.
5
A micromethod for quantitation of debrisoquine and 4-hydroxydebrisoquine in urine by liquid chromatography.
Braz J Med Biol Res. 2000 May;33(5):509-14. doi: 10.1590/s0100-879x2000000500004.
6
Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.
Chirality. 1991;3(1):14-8. doi: 10.1002/chir.530030104.
7
Evidence for the polymorphic oxidation of debrisoquine in the Thai population.泰国人群中异喹胍多态性氧化的证据。
Br J Clin Pharmacol. 1990 Feb;29(2):244-7. doi: 10.1111/j.1365-2125.1990.tb03627.x.
8
Prevalence of debrisoquine oxidation phenotypes in glaucoma patients.青光眼患者中异喹胍氧化表型的患病率。
Int Ophthalmol. 1989 Jan;13(1-2):91-3. doi: 10.1007/BF02028645.
9
Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.芬兰人群中的异喹胍氧化：口服避孕药对代谢率的影响。
Br J Clin Pharmacol. 1988 Dec;26(6):791-5. doi: 10.1111/j.1365-2125.1988.tb05321.x.
10
The effect of urine pH on debrisoquine phenotyping: application of an HPLC-method.尿液pH值对异喹胍表型分析的影响：高效液相色谱法的应用
Int J Clin Pharmacol Ther Toxicol. 1990 May;28(5):223-6.
引用本文的文献
1
Debrisoquine oxidation phenotype and susceptibility to lung cancer.异喹胍氧化表型与肺癌易感性
Br J Clin Pharmacol. 1990 Oct;30(4):653-6. doi: 10.1111/j.1365-2125.1990.tb03832.x.
本文引用的文献
1
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.对英国白人人群中异喹胍氧化遗传多态性的家系及群体研究。
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
2
Some observations on the oxidation phenotype status of Nigerian patients presenting with cancer.关于尼日利亚癌症患者氧化表型状态的一些观察
Cancer Lett. 1981 Feb;11(4):331-8. doi: 10.1016/0304-3835(81)90099-9.
3
Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.人体肝脏中去甲丙咪嗪4-羟化酶缺陷的证据。
Br J Clin Pharmacol. 1981 Jan;11(1):89-91. doi: 10.1111/j.1365-2125.1981.tb01108.x.
4
Defective oxidation of drugs: pharmacokinetic and therapeutic implications.药物氧化缺陷：药代动力学及治疗学意义
Clin Pharmacokinet. 1982 Jan-Feb;7(1):1-22. doi: 10.2165/00003088-198207010-00001.
5
Genetically determined oxidation capacity and the disposition of debrisoquine.遗传决定的氧化能力与异喹胍的代谢
Br J Clin Pharmacol. 1983 Apr;15(4):443-50. doi: 10.1111/j.1365-2125.1983.tb01528.x.
6
Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.代谢氧化表型作为肺癌易感性的标志物。
Nature. 1984;312(5990):169-70. doi: 10.1038/312169a0.
7
Pharmocogenetic implications of polymorphic debrisoquine hydroxylations.多态性异喹胍羟基化的药物遗传学意义
Q J Med. 1985 Feb;54(214):115-6.
8
Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.多态性药物氧化：药代动力学基础及实验指标比较
Br J Clin Pharmacol. 1986 Nov;22(5):541-50. doi: 10.1111/j.1365-2125.1986.tb02933.x.
9
Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus.
Arthritis Rheum. 1986 Jul;29(7):843-50. doi: 10.1002/art.1780290705.
10
Debrisoquine oxidation in an Australian population.澳大利亚人群中的异喹胍氧化作用。
Br J Clin Pharmacol. 1986 May;21(5):465-71. doi: 10.1111/j.1365-2125.1986.tb02827.x.
Zotero 插件